Serological Evidence of<i>Borrelia burgdorferi</i>in Patients with Morphea from West-Central Poland: An Original Paper and Review of Literature

Malewska-Woźniak, Anna; Jałowska, Magdalena; Lodyga, Martha; Osmola‐Mańkowska, Agnieszka; Adamski, Zygmunt

doi:10.1089/vbz.2020.2752

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, current guidelines do not recommend routine IgM and IgG antibody testing for Lyme disease in patients with morphea. This position is corroborated by a study conducted by Anna Malewska-Wozniak et al [13], which examined the prevalence of IgM and IgG antibody classes against Borrelia in 82 patients with morphea and 112 with psoriasis utilizing the conventional ELISA technique. The study revealed that IgM and IgG antibodies against Borrelia were identified only in 4% of blood samples obtained from patients diagnosed with morphea.…”

Section: Discussion Morphea After Vaccine Against Covid-19 Vaccine An...mentioning

confidence: 66%

Morphea caused by COVID-19 infection, first polish case report

Cisoń,

Białynicki-Birula

2024

Our Dermatol Online

View full text Add to dashboard Cite

Morphea, a localized scleroderma variant, is a rare dermatological condition characterized by fibrosis and thickening of the skin. While its etiology remains unclear, there have been reports of its association with viral infections, including COVID-19. We present a case of morphea in a 26-year-old female patient with a history of two episodes of COVID-19. The patient exhibited cutaneous lesions on her left forearm, bilateral axillae, and groin, accompanied by abdominal wall induration Laboratory investigations revealed no significant abnormalities, except for positive antinuclear antibodies (ANA) with various patterns. This case highlights the potential association between COVID-19 infection and the development of morphea, underscoring the importance of considering this relationship in patients presenting with dermatological manifestations following COVID-19. Further research is needed to elucidate the underlying mechanisms and optimize treatment strategies for such cases. Key words: COVID-19, Morphea, Post-COVID-19 Morphea, Skin diseases

show abstract

Section: Discussion Morphea After Vaccine Against Covid-19 Vaccine An...mentioning

confidence: 66%

Morphea caused by COVID-19 infection, first polish case report

Cisoń,

Białynicki-Birula

2024

Our Dermatol Online

View full text Add to dashboard Cite

show abstract

Scleroderma: Difficulties in classification, diagnosis, treatment

Shatokhina,

Lubivets,

Pereverzina

2023

Medicinskij alfavit

View full text Add to dashboard Cite

Localized scleroderma (LoS) is an autoimmune connective tissue disease with a variety of clinical manifestations. The dermatologist faces the difficulties of establishing a diagnosis and choosing the most appropriate therapy due to the relatively rare prevalence. This review article explores the challenges of classification, diagnosis, and treatment, as well as the factors that contribute to their occurrence. The greatest difficulties in diagnosing LoS that affected the prognosis and progression of the illness are: a delay in diagnosis, including early detection; omission of the active stage of LoS; difficulties in differential diagnosis; lack of association with Lyme borreliosis; low diagnostic value of laboratory and histological tests; limited use of sensitive instrumental methods for diagnosis; and monitoring the activity of LoS in a doctor’s practice. The main difficulties in treatment are the delay in starting treatment; the use of therapy methods with low evidence-based effectiveness; the rare prescription of highly effective approaches; the insufficient effectiveness of systemic drugs and phototherapy; difficulties in determining the volume, timing, and regimen of therapy for each subtype of LoS; the difficulty of achieving a remission; dependence of treatment approach on the doctor’s specialization; the lack of targeted drugs with evidence-based effectiveness in LoS; the lack of high-level evidence-based effectiveness and safety of therapy in LoS; difficulties in the correction of complications of Lo S.

show abstract

Serological Evidence ofBorrelia burgdorferiin Patients with Morphea from West-Central Poland: An Original Paper and Review of Literature

Cited by 2 publications

References 33 publications

Morphea caused by COVID-19 infection, first polish case report

Morphea caused by COVID-19 infection, first polish case report

Scleroderma: Difficulties in classification, diagnosis, treatment

Contact Info

Product

Resources

About